Literature DB >> 27252232

Idelalisib in the management of lymphoma.

Chan Yoon Cheah1, Nathan H Fowler2.   

Abstract

Inhibition of the phosphatidylinositol-3-kinase (PI3K) pathway as an anticancer therapeutic strategy was realized with the approval of the orally bioavailable small molecule PI3Kδ inhibitor idelalisib. In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provide a brief summary of the preclinical data, and describe the clinical experience with this agent in patients with lymphoma. We describe some of the idiosyncratic toxicities of this agent, some of the mechanisms of resistance, and some of the ongoing combination strategies.
© 2016 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27252232      PMCID： PMC5161010          DOI： 10.1182/blood-2016-02-702761

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  37 in total

1.  PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

Authors:  Sarah A Meadows; Francisco Vega; Adam Kashishian; Dave Johnson; Volker Diehl; Langdon L Miller; Anas Younes; Brian J Lannutti
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

2.  Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma.

Authors:  Amanda Psyrri; Sotirios Papageorgiou; Elisavet Liakata; Andreas Scorilas; Dimitra Rontogianni; Christos K Kontos; Pinelopi Argyriou; Dimitrios Pectasides; Nikolaos Harhalakis; Vassiliki Pappa; Aggeliki Kolialexi; Christina Economopoulou; Frida Kontsioti; Eirini Maratou; George Dimitriadis; Panagiota Economopoulou; Theofanis Economopoulos
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

3.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

Review 4.  Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

Authors:  Arpita Shah; Abhishek Mangaonkar
Journal:  Ann Pharmacother       Date:  2015-07-16       Impact factor: 3.154

Review 5.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 6.  Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.

Authors:  Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Mayo Clin Proc       Date:  2007-09       Impact factor: 7.616

Review 7.  Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.

Authors:  Srinivasan Ramanathan; Feng Jin; Shringi Sharma; Brian P Kearney
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

8.  Idelalisib-associated Colitis: Histologic Findings in 14 Patients.

Authors:  Anna-Sophie Weidner; Nicole C Panarelli; Julia T Geyer; Erica B Bhavsar; Richard R Furman; John P Leonard; Jose Jessurun; Rhonda K Yantiss
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

9.  MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.

Authors:  Heounjeong Go; Ji-Young Jang; Pil-Jong Kim; Young-Goo Kim; Soo Jeong Nam; Jin Ho Paik; Tae Min Kim; Dae Seog Heo; Chul-Woo Kim; Yoon Kyung Jeon
Journal:  Oncotarget       Date:  2015-06-20

10.  Constitutive AKT activation in follicular lymphoma.

Authors:  Ouardia I Yahiaoui; Jacques A Nunès; Céline Castanier; Raynier Devillier; Florence Broussais; Aurélie J Fabre; Dalila Naimi; Réda Bouabdallah; Daniel Olive; Luc Xerri
Journal:  BMC Cancer       Date:  2014-08-05       Impact factor: 4.430
View more
  45 in total

Review 1.  Novel immunotherapy approaches to follicular lymphoma.

Authors:  Christopher R Flowers; John P Leonard; Loretta J Nastoupil
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Authors:  Andres Forero-Torres; Radhakrishnan Ramchandren; Abdulraheem Yacoub; Michael S Wertheim; William J Edenfield; Paolo Caimi; Martin Gutierrez; Luke Akard; Carolina Escobar; Justin Call; Daniel Persky; Swaminathan Iyer; Douglas J DeMarini; Li Zhou; Xuejun Chen; Fitzroy Dawkins; Tycel J Phillips
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

3.  PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.

Authors:  Bola S Hanna; Philipp M Roessner; Annika Scheffold; Billy M C Jebaraj; Yasmin Demerdash; Selcen Öztürk; Peter Lichter; Stephan Stilgenbauer; Martina Seiffert
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

4.  Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Matthew Lunning; Julie Vose; Loretta Nastoupil; Nathan Fowler; Jan A Burger; William G Wierda; Marshall T Schreeder; Tanya Siddiqi; Christopher R Flowers; Jonathon B Cohen; Peter Sportelli; Hari P Miskin; Michael S Weiss; Susan O'Brien
Journal:  Blood       Date:  2019-11-21       Impact factor: 22.113

5.  Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.

Authors:  Montse Erra; Joan Taltavull; Angelique Gréco; Francisco Javier Bernal; Juan Francisco Caturla; Jordi Gràcia; María Domínguez; Mar Sabaté; Stéphane Paris; Salomé Soria; Begoña Hernández; Clara Armengol; Judit Cabedo; Mónica Bravo; Elena Calama; Montserrat Miralpeix; Martin D Lehner
Journal:  ACS Med Chem Lett       Date:  2016-11-30       Impact factor: 4.345

Review 6.  Current Treatment of Chronic Lymphocytic Leukemia.

Authors:  Krzysztof Jamroziak; Bartosz Puła; Jan Walewski
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 7.  Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.

Authors:  Ee Lyn Lim; Klaus Okkenhaug
Journal:  Immunology       Date:  2019-07       Impact factor: 7.397

Review 8.  PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

Authors:  Benjamin L Lampson; Jennifer R Brown
Journal:  Expert Opin Investig Drugs       Date:  2017-10-06       Impact factor: 6.206

Review 9.  The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.

Authors:  Trent Peng Wang; John Harwood Scott; Stefan Klaus Barta
Journal:  Ther Adv Hematol       Date:  2017-11-22

Review 10.  Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.

Authors:  Jeffrey D Cooney; Ricardo C T Aguiar
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.